Michael Glickman
Director, Center for Experimental Immuno-Oncology · New York Presbyterian Hospital
Credentials: · · · ·
History
PresentCenter for Experimental Immuno-Oncology · New York Presbyterian Hospital
Research
TOX is a critical regulator of tumour-specific T cell differentiation
Nature · 2019 · 936 citations
The mechanism of action of BCG therapy for bladder cancer--a current perspective
Review · Nature Reviews Urology · 2014 · 570 citations
Molecular Cell · 2000 · First of 3 authors · 504 citations
- GR
11 papers · 1 as a fellow
8 papers
- DB
7 papers · 1 as a resident
6 papers
- MK
5 papers
4 papers
- JC
4 papers
- KS
4 papers
Grants
- 2026–2031
Determinants of TB Control, Relapse, and Reinfection
National Institute of Allergy and Infectious Diseases · P01
PI · $2.2M · Weill Medical Coll of Cornell Univ
- 2026–2031
Hematopoietic Stem Cell Encoded Anti-Tumor Immunity: Mechanisms and Function
National Cancer Institute · R01
Contact PI · $745.5K · Sloan-Kettering Inst Can Research
- 2005–2031
Novel Pathway of DNA Inter-Strand Crosslink Repair in Mycobacteria
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $11.1M · Sloan-Kettering Inst Can Research
- 2026–2029
Chalkophore Mediated Respiratory Oxidase Flexibility and M. tuberculosis Virulence
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $3.2M · Sloan-Kettering Inst Can Research